TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19008868
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (96.3 mg of catechins per day)
Study: 15206989
Drug: CIC 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIC 400 microg once daily
Study: 15206989
Drug: FP 250
Normalized name: Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rIX-FP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FP 250 microg twice daily
Study: 11207639
Drug: Dexamethasone (long
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (long course: 42-day tapering course)
Study: 11207639
Drug: Dexamethasone (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (both treatment regimens)
Study: 3182309
Drug: Melphalan (L-PAM)
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Melphalan (L-PAM) and prednisone (pred) therapy for 12 weeks followed by total bone marrow irradiation (TBMI) at a dose of 1500 cGy
Study: 3182309
Drug: Total bone
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total bone marrow irradiation (TBMI) at a dose of 1500 cGy
Study: 31038755
Drug: FMT capsules
Normalized name: [18F]FMT
DrugBank: 6-[18F]-Fluoro-L-m-tyrosine (DB17621)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FMT capsules
Study: 27269279
Drug: Bevacizumab (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (1.25 mg/0.05 ml)
Study: 23354008
Drug: AGEs inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGEs inhibitor (benfotiamine [50 mg]+pyridoxamine [50 mg]+methylcobalamin [500 µg])
Study: 9629989
Drug: Caffeine (CAF)
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine (CAF) - single oral dose (7 mg x kg(‐1))
Study: 9629989
Drug: Creatine (CRE)
DrugBank: Creatine (DB00148)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Creatine (CRE) - repeated oral doses (3 x 100 mg x kg(‐1) x day(‐1)) for 3 days
Study: 9629989
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of caffeine and creatine (CAF + CRE)
Study: 30172659
Drug: DHA +
Normalized name: PNV-DHA + Docusate Softgel
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA + EPA (4 g daily)
Study: 15855574
Drug: Insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin detemir 0.1 units/kg
Study: 15855574
Drug: Insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin detemir 0.2 units/kg
Study: 15855574
Drug: Insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin detemir 0.4 units/kg
Study: 15855574
Drug: Insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin detemir 0.8 units/kg
Study: 15855574
Drug: Insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin detemir 1.6 units/kg
Study: 15855574
Drug: Insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin detemir 0.29 units/kg
Study: 2186616
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron supplementation (ferrous sulfate or ferrous gluconate)
Study: 6990208
Drug: Once-a-day spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once-a-day spironolactone therapy
Study: 6990208
Drug: Twice-a-day spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-a-day spironolactone therapy
Study: 6990208
Drug: Twice-a-day therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-a-day therapy
Study: 30612238
Drug: Standard oncology
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oncology treatment
Study: 26383249
Drug: Subtracting the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subtracting the standing oxygen cost (4.8 ± 0.4 mL·kg(‐1)·min(‐1))
Study: 19021596
Drug: Subconjunctival injection
Normalized name: STREPTOMYCES GRISEUS 0.05 g in 1 mL SUBCONJUNCTIVAL INJECTION, SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subconjunctival injection of 2.5 mg bevacizumab
Study: 19021596
Drug: Subconjunctival injection
Normalized name: STREPTOMYCES GRISEUS 0.05 g in 1 mL SUBCONJUNCTIVAL INJECTION, SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subconjunctival injection of 5.0 mg bevacizumab
Study: 19021596
Drug: Subconjunctival injection
Normalized name: STREPTOMYCES GRISEUS 0.05 g in 1 mL SUBCONJUNCTIVAL INJECTION, SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subconjunctival injection of 1.25 mg bevacizumab
Study: 17982319
Drug: diclofenac 75
Normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: diclofenac 75 mg (plus orphenadrin 30 mg)
Study: 17982319
Drug: paracetamol 1
Normalized name: Paracetamol 1 g oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: paracetamol 1 g
Study: 9848296
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive (OC) pretreatment for 14 days
Study: 388168
Drug: Cimetidine 1200
Normalized name: cimetidine 1200 mg-0.9%/500 mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 1200 mg daily
Study: 28182535
Drug: Economic analysis
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Economic analysis of treatment groups
Study: 19255407
Drug: Natalizumab 300
Normalized name: natalizumab 300 MG in 15 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natalizumab 300 mg IV once every 4 weeks plus GA 20 mg subcutaneously once daily for ≤ 20 weeks
Study: 15196161
Drug: Placebo (serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (serum saline injection)
Study: 11772799
Drug: Cisapride 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 0.3 mg/kg orally 1 h before surgery and placebo 6 h later (Group C1)
Study: 8087821
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg TNTG applied for 16 h with a 'nitrate‐free' interval of 8 h
Study: 8087821
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg TNTG applied for 16 h followed by a 'nitrate‐low' interval of 5 mg applied for 8 h
Study: 2587133
Drug: Vitamin K1
Normalized name: vitamin K1
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K1 (10 mg intramuscularly, repeated if delivery did not occur in 4 days, followed by 20 mg orally daily until the end of the 34th week if pregnancy continued)
Study: 782504
Drug: 1% Ciclopirox
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% Ciclopirox solution
Study: 29127060
Drug: G-CSF (lenograstim)
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (lenograstim) 15 μg/kg for 5 days
Study: 29127060
Drug: G-CSF for
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF for 5 days followed by leukapheresis and intravenous infusion of CD133-positive stem cells (0.2 × 10^6 cells per kg per infusion)
Study: 26456672
Drug: Isosorbid mononitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isosorbid mononitrate 20 mg tablet once daily applied vaginally until delivery
Study: 18978105
Drug: Placebo vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo vaginal tablets
Study: 29100251
Drug: 20 mg/day
Normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/day memantine
Study: 23583234
Drug: 2000 IU/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 IU/day alpha-tocopherol plus 20 mg/day memantine
Study: 22360820
Drug: rosuvastatin 40
Normalized name: rosuvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 40 mg (RSV40)
Study: 22360820
Drug: rosuvastatin 20
Normalized name: rosuvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 20 mg (RSV20)
Study: 22360820
Drug: atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: atorvastatin 80 mg (ATV80)
Study: 20820832
Drug: TMC207 (novel
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMC207 (novel agent)
Study: 17588187
Drug: AT nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AT nerve block with LA (Bupivacaine, 2.5 mg/ml)
Study: 17588187
Drug: IA injection
Normalized name: factor VIIa Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: IA injection with LA (Bupivacaine, 2.5 mg/ml)
Study: 17588187
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection (isotonic saline)
Study: 16307966
Drug: Tamoxifen (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (10 mg twice daily for 10 days)
Study: 12212873
Drug: Computerized injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerized injection device (Wand)
Study: 9466020
Drug: Standard heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard heparin and protamine management (Group 1)
Study: 9466020
Drug: Heparin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin and protamine by in vitro titration (Group 2)
Study: 9466020
Drug: Heparin dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin dose titrated (Group 3)
Study: 9466020
Drug: Protamine dose
Normalized name: protamines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protamine dose titrated (Group 4)
Study: 777074
Drug: 0.22 mg
Normalized name: urea 0.22 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.22 mg of tartrazine
Study: 31866161
Drug: Non-treatment control
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-treatment control Group (n=21)
Study: 30683591
Drug: Letrozole and
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole and Clomiphene Citrate (CC) - 2.5 mg letrozole and 50 mg CC daily on cycle days 3–7 for one treatment cycle
Study: 30683591
Drug: Letrozole alone
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole alone - 2.5 mg letrozole daily on cycle days 3–7 for one treatment cycle
Study: 19370427
Drug: Daily pretreatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily pretreatment megavoltage computed tomography (MVCT)
Study: 19370427
Drug: Daily MVCT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily MVCT
Study: 14607494
Drug: RANKL protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RANKL protein levels in peri-implant tissues of patients with implant failure
Study: 14607494
Drug: OPG protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPG protein levels in peri-implant tissues
Study: 14607494
Drug: RANKL mRNA
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: RANKL mRNA expression in peri-implant tissues
Study: 11303975
Drug: Gabexate mesilate
Normalized name: mesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabexate mesilate 900 mg/day
Study: 11303975
Drug: Gabexate mesilate
Normalized name: mesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabexate mesilate 1,500 mg/day
Study: 8195331
Drug: Progesterone (1
Normalized name: Fluorofuranylnorprogesterone (18F)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone (1 mmol/l)
Study: 3539980
Drug: Nalmefene administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalmefene administration
Study: 26450586
Drug: REFOCUS intervention,
Approvals — FDA: no, EMA: no, PMDA: no
Description: REFOCUS intervention, which includes recovery-promoting relationships and working practices, specific details on dosage and duration not available.
Study: 18451674
Drug: Treatment time
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment time (t) in NCDS
Study: 18451674
Drug: Dose targeting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose targeting observational studies (OS)
Study: 11088036
Drug: Teicoplanin (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin (15 mg/kg single dose)
Study: 11088036
Drug: Cefazolin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin (2 g initial dose, followed by 1 g every 8 hours for 6 doses over 2 days)
Study: 8270290
Drug: Kamalahar 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kamalahar 500 mg three times a day for 15 days
Study: 8270290
Drug: Kamalahar 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kamalahar 500 mg
Study: 29024542
Drug: Momelotinib tablet,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Momelotinib tablet, 200 mg
Study: 29024542
Drug: Momelotinib tablet
Normalized name: momelotinib
DrugBank: Momelotinib (DB11763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Momelotinib tablet with low-fat meal
Study: 29024542
Drug: Momelotinib tablet
Normalized name: momelotinib
DrugBank: Momelotinib (DB11763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Momelotinib tablet with high-fat meal
Study: 29024542
Drug: Momelotinib tablet
Normalized name: momelotinib
DrugBank: Momelotinib (DB11763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Momelotinib tablet with omeprazole
Study: 22079088
Drug: Sitaxsentan 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitaxsentan 50 or 100 mg
Study: 18296124
Drug: Donepezil 10
Normalized name: donepezil 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil 10 mg per day (n=84)
Study: 2781858
Drug: Combined rabies
Normalized name: rabies virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined rabies vaccine with aluminium hydroxide-adsorbed tetanus toxoid on days 0 and 21
Study: 2781858
Drug: Combined rabies
Normalized name: rabies virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined rabies vaccine with aluminium hydroxide-adsorbed tetanus toxoid
Study: 27927658
Drug: Liberal transfusion
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal transfusion strategy (Hb ≤100 g/L)
Study: 27927658
Drug: Restrictive transfusion
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive transfusion strategy (Hb ≤80 g/L)
Study: 24438370
Drug: Bazedoxifene (BZA)
DrugBank: Bazedoxifene (DB06401)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bazedoxifene (BZA) 20 mg/Conjugated Estrogens (CE) 0.45 or 0.625 mg
Study: 24438370
Drug: Conjugated Estrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated Estrogens (CE) 0.45 mg/Medroxyprogesterone Acetate (MPA) 1.5 mg
Study: 24438370
Drug: Bazedoxifene (BZA)
DrugBank: Bazedoxifene (DB06401)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bazedoxifene (BZA) 20 mg
Study: 17632131
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg trospium chloride once daily
Study: 11751144
Drug: BMS 284756
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BMS 284756 (600 mg single dose)
Study: 9526970
Drug: Metformin 1700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1700 mg
Study: 8011237
Drug: Subcutaneous rIL‐2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous rIL‐2 (0.2 x 10(6), 0.7 x 10(6), or 2 x 10(6) units/m2 per day for 5 consecutive days)
Study: 8011237
Drug: Subcutaneous rIL‐2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous rIL‐2
Study: 8011237
Drug: Subcutaneous rIL‐2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous rIL‐2 (highest dose)
Study: 2544152
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin-DHE (LMWH-DHE)
Study: 2544152
Drug: Conventional heparin-DHE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional heparin-DHE (heparin-DHE/A)
Study: 23918952
Drug: Apatinib 850
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib 850 mg once daily (group B)
Study: 23918952
Drug: Apatinib 425
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib 425 mg twice daily (group C)
Study: 22127969
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral cyclophosphamide (CYC)
Study: 22127969
Drug: CYC cumulative
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: CYC cumulative dose
Study: 9588607
Drug: 6% carbohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% carbohydrate beverage ingestion (4 mL x kg(‐1) every 15 min during exercise)
Study: 985152
Drug: Adjuvant nitrosourea
Normalized name: Bischloroethyl nitrosourea
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjuvant nitrosourea chemotherapy (carmustine, lomustine, or semustine)
Study: 28032910
Drug: Everolimus co-administration
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus co-administration with octreotide LAR
Study: 18785848
Drug: Low-power He-Ne
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-power He-Ne laser (output power 0.2 mW) for 10 min, applied eight times in the first 3-month period after non-surgical mechanical periodontal treatment.
Study: 18785848
Drug: Control sites
Normalized name: PAD,BITE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control sites received no additional treatment after non-surgical mechanical periodontal treatment.
Study: 9034838
Drug: Latanoprost 0.0015%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latanoprost 0.0015% twice daily
Study: 8302442
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of Nicardipine retard twice a day (b.i.d.) for 8 weeks
Study: 8302442
Drug: Captopril in
Normalized name: Product containing captopril in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril in a dose of 25 mg (b.i.d.) for 8 weeks
Study: 2957900
Drug: Selective coronary
Normalized name: Glebionis coronaria whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective coronary injection of echocontrast medium through the central lumen of the angioplasty catheter before balloon inflation (group A)
Study: 2957900
Drug: Intracoronary echocontrast
Normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary echocontrast injections (both groups)
Study: 26397376
Drug: Antibiotics for
Normalized name: ANTIBIOTICS FOR TOPICAL USE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics for four days
Study: 26397376
Drug: Antibiotics until
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics until two days after clinical symptom resolution
Study: 25133794
Drug: Fenofibric acid
Normalized name: Fenofibric Acid
DrugBank: Fenofibric acid (DB13873)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibric acid 135 mg once daily for 1 year
Study: 21956447
Drug: Psilocybin (260
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin (260 μg/kg p.o.)
Study: 21956447
Drug: Psilocybin (260
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin (260 μg/kg p.o.) + Ketanserin (40 mg p.o.)
Study: 20159701
Drug: Postoperative general
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative general anesthesia and intravenous analgesia (group A)
Study: 19123322
Drug: Tangyikang (TYK)
Normalized name: Tykerb
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tangyikang (TYK) combined with insulin therapy
Study: 19123322
Drug: Insulin therapy
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin therapy alone (Control)
Study: 15850470
Drug: PEG-IFN alpha-2a
Normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PEG-IFN alpha-2a 180 microg/week + RBV 1000 or 1200 mg/day + AMA 200 mg/day
Study: 15850470
Drug: IFN alpha-2a
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN alpha-2a 3 MU tiw + RBV 1000 or 1200 mg/day + AMA 200 mg/day
Study: 15850470
Drug: IFN alpha-2a
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN alpha-2a 3 MU tiw + RBV 1000 or 1200 mg/day
Study: 12861852
Drug: Tramadol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (50 mg total dose)
Study: 10577848
Drug: One cycle
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One cycle of high-dose cytarabine
Study: 10577848
Drug: Three or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three or more cycles of high-dose cytarabine
Study: 8733038
Drug: Nifedipine (20‐40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20‐40 mg twice daily)
Study: 8733038
Drug: Lisinopril and
Normalized name: lisinopril and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril and Nifedipine
Study: 1289173
Drug: Pancreatic extracts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancreatic extracts (acid‐protected microtablets; Panzytrat ‐20,000; 5 x 2 capsules/day; proteases/capsule 1,000 Pharmacopoea europaea units) for 14 days followed by placebo for another 14 days.
Study: 6146033
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g sucrose taken at the end of a mixed meal (meal B)
Study: 29323577
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptive (COC) - 1.5 mg estradiol and 2.5 mg nomegestrolacetate
Study: 27825415
Drug: Intranasal DEX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal DEX 1 μg/kg (Group D1)
Study: 27825415
Drug: Intranasal DEX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal DEX 2 μg/kg (Group D2)
Study: 23589502
Drug: Infused green
Normalized name: acid green 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infused green tea (0.75% w/v, 180 mg total C)
Study: 23589502
Drug: Infused green
Normalized name: acid green 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infused green tea (medium and high doses)
Study: 17676393
Drug: Aspirin (81
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (81 mg q.d.) plus celecoxib (200 mg q.d.)
Study: 17676393
Drug: Aspirin (81
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (81 mg q.d.) plus naproxen (500 mg b.i.d.)